Evaluation of Nordmann, Dortet, and Poirel test for the identification of extended spectrum betalactamase production among urinary isolates of Escherichia coli

R. Deepa; Mythry Ravichandran; S. Thasneem Banu; R. Sharmila

doi:10.4103/JLP.JLP_154_16

Journal of Laboratory Physicians, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · J Lab Physicians 2017; 9(04): 269-272
DOI: 10.4103/JLP.JLP_154_16

Original Article

Evaluation of Nordmann, Dortet, and Poirel test for the identification of extended spectrum betalactamase production among urinary isolates of Escherichia coli

R. Deepa

Institute of Microbiology, Madras Medical College and Government General Hospital, Chennai, Tamil Nadu, India

,

Mythry Ravichandran

Institute of Microbiology, Madras Medical College and Government General Hospital, Chennai, Tamil Nadu, India

,

S. Thasneem Banu

Institute of Microbiology, Madras Medical College and Government General Hospital, Chennai, Tamil Nadu, India

,

R. Sharmila

Institute of Microbiology, Madras Medical College and Government General Hospital, Chennai, Tamil Nadu, India

› Institutsangaben

Abstract

als PDF herunterladen

Abstract

CONTEXT: Current phenotypic techniques for extended spectrum beta lactamase (ESBL) detection can be interpreted after 24 h of incubation only, resulting in a delay in initiating therapy. Nordmann, Dortet, and Poirel (NDP) in 2012 proposed a novel test named ESBL NDP to overcome this limitation.

AIMS: This study aimed to evaluate the ESBL NDP test for the identification of ESBL among Escherichia coli isolates against the Clinical Laboratory Standards Institute-recommended phenotypic confirmatory method.

SETTINGS AND DESIGN: This cross-sectional study was conducted over a period of 3 months on a sample size of 100.

SUBJECTS AND METHODS: One hundred nonduplicate clinically significant E. coli urinary isolates positive by initial screening test for ESBL were subjected to the ESBL NDP test and phenotypic confirmatory test. The NDP test was evaluated by determining the sensitivity, specificity, kappa value, and confidence interval (CI) for kappa.

RESULTS: The phenotypic confirmatory test and the ESBL NDP test were positive in 82% and 63% of the isolates, respectively. ESBL NDP test had a sensitivity and specificity of 76% and 100%, positive and negative predictive values of 100% and 48%, respectively, kappa value of 0.54 (moderate agreement), and 95% CI for kappa of 0.43–0.66. The time to positivity was 1 h in 93.6% of the isolates.

CONCLUSION: The NDP test showed a good specificity, with time to positivity of 1 h. The low sensitivity could be due to the difference in the phenotypic type of ESBL producer and technical reasons.

Key words

Extended spectrum beta lactamase - Nordmann - Dortet - and Poirel test - phenotypic confirmatory test

PDF (644 kb)

Referenzen

References
1 Bradford PA. Extended-spectrum beta-lactamases in the 21^st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
2 Paterson DL, Bonomo RA. Extended-spectrum-lactamases: A clinical update. Clinical microbiology reviews 2005;18:657-86.
3 Eshwarappa M, Dosegowda R, Aprameya IV, Khan MW, Kumar PS, Kempegowda P. Clinico-microbiological profile of urinary tract infection in South India. Indian J Nephrol 2011;21:30-6.
4 Abhilash KP, Veeraraghavan B, Abraham OC. Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in a tertiary care teaching hospital in South India. J Assoc Physicians India 2010;58 Suppl: 13-7.
5 Sharma M, Pathak S, Srivastava P. Prevalence and antibiogram of extended spectrum ß-lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diagn Res 2013;7:2173-7.
6 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fourth Informational Supplement. CLSI Document M100-S24. Wayne PA: Clinical and Laboratory Standards Institute; 2014.
7 Nordmann P, Dortet L, Poirel L. Rapid detection of extended-spectrum-ß-lactamase-producing Enterobacteriaceae. J Clin Microbiol 2012;50:3016-22.
8 Dortet L, Poirel L, Nordmann P. Rapid detection of extended-spectrum-ß-lactamase-producing Enterobacteriaceae from urine samples by use of the ESBL NDP test. J Clin Microbiol 2014;52:3701-6.
9 Tille PM. Bailey and Scott's Diagnostic Microbiology. 13^th ed. St. Louis, Missouri: Elsevier; 2007. p. 926-9.
10 McHugh ML. Interrater reliability: The kappa statistic. Biochem Med (Zagreb) 2012;22:276-82.
11 Nataro JP, Bopp CA, Fields PI, Kaper JB, Strockbine NA. Escherichia, Salmonella and Shigella. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. 9^th ed., Vol. 1, Ch. 43. Washington, DC: ASM Press; 2007. p. 670-87.
12 Poirel L, Fernández J, Nordmann P. Comparison of three biochemical tests for rapid detection of extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Clin Microbiol 2016;54:423-7.
13 Taha S, Youssef N, Elkazaz A, Ramadan H. Detection of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae using the ESBL NDP test and flow cytometric assay in comparison to the standard disc diffusion. African Journal of Microbiology Research 2016;10:238-44.
14 Renvoisé A, Decré D, Amarsy-Guerle R, Huang TD, Jost C, Podglajen I, et al. Evaluation of the ßLacta test, a rapid test detecting resistance to third-generation cephalosporins in clinical strains of Enterobacteriaceae. J Clin Microbiol 2013;51:4012-7.